The Leuprolide Acetate Injection Kit, cataloged under National Stock Number 6505-01-363-0935, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Tap Pharmaceutical Products Inc. Government technical data includes 2 specifications, cited from the U.S. Government catalog. The record lists 1 manufacturer part number for this item, enabling identification through both NSN and commercial part number lookups. 1 additional reference document (drawings, advisory and superseded references) is recorded in the U.S. Government catalog. Current acquisition status: Active.
| Parameter | Value |
|---|---|
| NSN | 6505-01-363-0935 |
| Primary Part Number | NDC00300-3626-28 |
| Item Name | Leuprolide Acetate Injection Kit |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Tap Pharmaceutical Products Inc |
| Status | ACTIVE |
| Protective Storage Feature | ANTINEOPLASTIC DRUG AND REQUIRES REFRIGERATION STORAGE BETWEEN 2 TO 8 DEG CELSIUS AND SUBJECT TO DAMAGE BY FREEZING |
| Usage Design | FOR USE IN THE TREATMENT OF PROSTATIC CANCER |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Part Number | Manufacturer |
|---|---|
| NDC00300-3626-28 PRIMARY | Tap Pharmaceutical Products Inc (USA) |
| Reference | Meaning |
|---|---|
| LUPRON | 3/1 Design control — primary reference Tap Pharmaceutical Products Inc |
NSN 6505-01-363-0935 is a Leuprolide Acetate Injection Kit, manufactured by Tap Pharmaceutical Products Inc, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-363-0935 has 1 manufacturer part number on file: NDC00300-3626-28 (Tap Pharmaceutical Products Inc).
Key specifications for NDC00300-3626-28: Special Features: STERILE; AQUEOUS SOLUTION; 5 MG. LEUPROLIDE ACETATE PER ML.; Protective Storage Feature: ANTINEOPLASTIC DRUG AND REQUIRES REFRIGERATION STORAGE BETWEEN 2 TO 8 DEG CELSIUS AND SUBJECT TO DAMAGE BY FREEZING; Usage Design: FOR USE IN THE TREATMENT OF PROSTATIC CANCER. 2 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.